Subtle Marketing Strategies
In India, a wave of subtle marketing for GLP-1 based weight-loss drugs is sweeping across various platforms, from gentle awareness campaigns to pervasive
social media pushes. These injections, designed to mimic gut hormones, offer significant weight loss benefits alongside their primary therapeutic uses. For example, an Eli Lilly campaign featuring actors Ratna Pathak Shah and Supriya Pathak aims to destigmatize obesity by portraying it as a treatable chronic disease. Similarly, Novo Nordisk's "wegowithyou" campaign cleverly incorporates a fitness mantra to encourage seeking medical advice for weight management. These approaches, while seemingly educational, raise concerns about whether they serve as indirect endorsements for specific medications like Mounjaro and Wegovy. The rising visibility of these drugs, coupled with attractive advertisements and influencer endorsements, has created a strong desire among the public to explore them as potential solutions, sometimes even before thorough medical evaluation or lifestyle interventions.
Navigating Regulatory Loopholes
The promotional surge for GLP-1 drugs in India, including big hoardings, newspaper ads, and social media content, largely originates from the companies behind these new medications. A key observation is that these advertisements meticulously avoid naming any specific drug or brand. This deliberate omission exploits a legal loophole, as the Drugs and Magic Remedies (Objectionable Advertisements) Act prohibits the marketing of drugs for certain listed conditions, such as obesity. However, if the drug's name is not mentioned, regulatory bodies struggle to initiate action. A former drug regulator highlighted that while the act covers around 54 medical conditions, enforcement is challenging without direct drug identification. This strategy allows companies to present their promotions as general disease awareness campaigns. Past instances, like a case against GSK in the 90s, demonstrate how companies have learned to navigate these regulations, making it difficult for authorities to take substantial punitive action, often resulting in minor penalties that fail to deter future violations.
Official Advisory Issued
In response to the burgeoning promotional activities surrounding GLP-1 receptor agonists and similar prescription drugs for obesity and metabolic disorders, India's drug regulator, the Central Drugs Standard Control Organisation (CDSCO), has issued a formal advisory. This statement explicitly cautions that pharmaceutical companies might be engaging in direct or indirect promotional efforts, including disease awareness campaigns and digital outreach, that function as surrogate advertisements for these prescription-only medications. The CDSCO emphasized that any such promotional activity, even if framed as awareness, will be viewed seriously and could be classified as irrational or misleading marketing practices. This advisory underscores the regulatory body's stance against disguised marketing and highlights their intention to take a firm approach towards ensuring truthful and responsible promotion of these potent medications.
Challenges in Distribution
Beyond direct advertising, a significant push for weight-loss drugs is being channeled through various health and fitness programs. Renowned fitness brands, such as Cult.fit, are now offering 'doctor-led' programs that incorporate GLP-1 medications. This trend is concerning because these powerful drugs, which affect the brain and stomach, are intended for individuals with morbid obesity and multiple associated health risks. According to Dr. V Mohan, Chairman of Dr. Mohan's Diabetes Specialist Centre, these medications should only be prescribed by specialists like endocrinologists, diabetologists, or cardiologists in specific cases. However, there are reports of non-medical personnel also dispensing these drugs, and in some areas, pharmacies are reportedly selling them without requiring a prescription. This lack of stringent oversight, coupled with intense market competition, makes vigilance difficult, as pharmacists might be tempted to sell to consumers who present forged or AI-generated prescriptions. The availability of these drugs online with on-call doctor consultations further complicates regulatory control.
Retailer Push and Market Stocking
The sales strategy for generic weight-loss drugs in India involves a significant push from stockists aiming to move inventory quickly. Companies that have recently launched their products, priced between Rs 1,300 to Rs 7,000 per month, are aggressively promoting these injectables to retailers. Given that these medications require cold storage at 2-8 degrees Celsius, pharmacies are incentivized to sell them promptly to avoid spoilage. Stockists admit that these products are pre-paid and unlikely to be returned, creating pressure to move them down the supply chain. This has led to a situation where market experts note substantial primary sales figures, indicating that companies are building up significant inventory in the market, even if not all of it has reached retailers yet. This aggressive stocking and distribution model further fuels the widespread availability and promotion of these drugs.
Building Trust and Caution
Establishing trust in newer weight-loss drug brands takes time, according to Dr. Anoop Misra, Chairman of Fortis C-Doc. He notes that he personally took about a year to feel comfortable prescribing innovator molecules before considering generics, even after patents expired. He emphasizes the importance of observing the efficacy of new brands over time. Dr. Misra also points out that advertising significantly influences prescription rates, potentially overshadowing the effectiveness of existing, more affordable treatments. He stresses that drug efficacy can vary greatly among individuals, necessitating significant caution. However, there's a potential upside: the widespread online information about weight-loss drugs might have already created a receptive market. For some store owners, these campaigns may have simply communicated that these medications are now more accessible to those who genuinely require them for medical reasons.
